Associated Genetic Biomarkers
CYSLTR2 is altered in 1.58% of all cancers with prostate adenocarcinoma, lung adenocarcinoma, colon adenocarcinoma, uterine corpus leiomyosarcoma, and breast invasive ductal carcinoma having the greatest prevalence of alterations .
The most common alterations in CYSLTR2 are CYSLTR2 Loss (0.94%), CYSLTR2 Mutation (0.53%), CYSLTR2 Amplification (0.08%), CYSLTR2 E343K (0.02%), and CYSLTR2 R136H (0.02%) .
CYSLTR2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CYSLTR2 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with CYSLTR2 status in the inclusion eligibility criteria most commonly target melanoma .
The most frequent alteration to serve as an inclusion eligibility criterion is CYSLTR2 Mutation .
Ipilimumab, nivolumab, and pegargiminase are the most frequent therapies in trials with CYSLTR2 as an inclusion criteria .
Significance of CYSLTR2 in Diseases
Uveal Melanoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.